Dapagliflozin in Allo-HCT for aGVHD
ConditionGraft-versus-host Disease (GVHD)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe First Affiliated Hospital of Soochow University
About this trial
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.
Eligibility criteria
Qualifiers
Age 18 to 65 years old.
Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.
Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.
With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
Disqualifiers
With other malignancies.
With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.
With a history of allergies to Dapagliflozin.
With type 1 diabetes or a history of ketoacidosis.
Trial design
Treatments tested in this trial
- Dapagliflozin (DAPA)
Treatment groups
72 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov